Toward Correlation in In Vivo and In Vitro Nanotoxicology Studies

Xie J. Lee S. , and Chen X. , “Nanoparticle-Based Theranostic Agents,” Advanced Drug Delivery Reviews 62, no. 11 (2010): 1064–1079.

Lin Y.-S. Hurley K. R. , and Haynes C. L. , “Critical Considerations in the Biomedical Use of Mesoporous Silica Nanoparticles,” Journal of Physical Chemistry Letters 3, no. 3 (2012): 364–374.

Etheridge M. L. Campbell S. A. Erdman A. G. Haynes C. L. Wolf S. M. , and McCullough J. , “The Big Picture on Nanomedicine: The State of Investigational and Approved in Nanomedicine Products,” Nanomedicine: Nanotechnology, Biology, and Medicine (2012): In press.

von Escherbach A. C. , Nanotechnology: A Report of the U.S. Food and Drug Administration Nanotechnology Task Force (Rockville, MD: U.S. Food and Drug Administration, 2007).

Marquis B. J. Maurer-Jones M. A. Ersin O. E. Lin Y.-S. , and Haynes C. L. , “The Bench Scientist's Perspective on the Unique Considerations in Nanoparticle Regulation,” Journal of Nanoparticle Research 13, no. 4 (2011): 1389–1400.

Marquis B. J. Love S. A. Braun K. L. , and Haynes C. L. , “Analytical Methods to Assess Nanoparticle Toxicity,” Analyst 134, no. 3 (2009): 425–439; Maurer-Jones M. A. Bantz K. C. Love S. A. Marquis B. J. , and Haynes C. L. , “Toxicity of Therapeutic Nanoparticles,” Nanomedicine 4, no. 2 (2009): 219–241; Love S. A. Maurer-Jones M. A. Thompson J. W. Lin Y.-S. , and Haynes C. L. , “Assessing Nanoparticle Toxicity,” Annual Review of Analytical Chemistry 5 (2012): 181–205.

Id.

See Marquis , supra note 5.

Pari Pharma GmbH, “L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients,” U.S. National Institutes of Health, available at <http://www.clinicaltrials.gov/ct2/show/NCT01334892?term=NCT01334892&rank=1> (last visited November 8, 2012).

M.D. Anderson Cancer Center, Aerosol l9-nc and Temozolomide in Ewing's Sarcoma, U.S. National Institutes of Health, available at <http://www.clinicaltrials.gov/ct2/show/NCT00492141?term=NCT00492141&rank=1> (last visited November 8, 2012).

Oberdorster G. Stone V. , and Donaldson K. , “Toxicology of Nanoparticles: A Historical Perspective,” Nanotoxicology 1, no. 1 (2007): 2–25.

See Love , supra note 6.

Horie M. Fukui H. Nishio K. Endoh S. Kato H. Fujita K. Miyauchi A. Nakamura A. Shichiri M. Ishida N. Kinugasa S. Morimoto Y. Niki E. Yoshida Y. , and Iwahashi H. , “Evaluation of Acute Oxidative Stress Induced by Nio Nanoparticles In Vivo and In Vitro,” Journal of Occupational Health 53, no. 2 (2011): 64–74; Warheit D. B. Sayes C. M. , and Reed K. L. , “Nanoscale and Fine Zinc Oxide Particles: Can In Vitro Assays Accurately Forecast Lung Hazards Following Inhalation Exposures?” Environmental Science and Technology 43, no. 20 (2009): 7939–7945; Tabet L. Bussy C. Setyan A. Simon-Deckers A. Rossi M. J. Boczkowski J. , and Lanone S. , “Coating Carbon Nanotubes with a Polystyrene-Based Polymer Protects against Pulmonary Toxicity,” Particle and Fibre Toxicology 8 (2011): 3; Rushton E. K. Jiang J. Leonard S.S. Eberly S. Castranova V. Biswas P. Elder A. Han X. Gelein R. Finkelstein J. and Oberdorster G. , “Concept of Assessing Nanoparticle Hazards Considering Nanoparticle Dosemetric and Chemical/Biological Response Metrics,” Journal of Toxicology and Environmental Health Part A, 73 (2010): 445–461.

See Horie , supra note 13.

See Warheit , supra note 13.

Wang X. Xia T. Addo N. S. Ji Z. Lin S. Meng H. Chung C.-H. George S. Zhang H. Wang M. Li N. Yang Y. Castranova V. Mitra S. Bonner J. , and Nel A. , “Dispersal State of Multiwalled Carbon Nanotubes Elicits Profibrogenic Cellular Responses That Correlate with Fibrogenesis Biomarkers and Fibrosis in the Murine Lung,” ACS Nano 5, no. 12 (2011): 9772–9787.

Id.

Cryan S.-A. Sivadas N. , and Garcia-Contreras L. , “In Vivo Animal Models for Drug Delivery across the Lung Mucosal Barrier,” Advanced Drug Delivery Reviews 59, no. 11 (2007): 1133–1151.

See Love , supra note 6.

Melo P. S. Marcato P. D. Hubert S. C. Ferreira I. R. de P. L. B. Almeida A. B. A. Duran N. Torsoni S. Seabra A. B. , and Alves O. L. , “Nanoparticles in Treatment of Thermal Injured Rats: Is It Safe?” Journal of Physics: Conference Series 304, no. 1(2011): 012027/012021–012027/012028.

Samberg M. E. Oldenburg S. J. , and Monteiro-Riviere N. A. , “Evaluation of Silver Nanoparticle Toxicity in Skin In Vivo and Keratinocytes In Vitro,” Environmental Health Perspectives 118, no. 3 (2010): 407–413.

Murray A. R. Kisin E. Leonard S. S. Young S. H. Kommineni C. Kagan V. E. Castranova V. , and Shvedova A. A. , “Oxidative Stress and Inflammatory Response in Dermal Toxicity of Single-Walled Carbon Nanotubes,” Toxicology 257, no. 3 (2009): 161–171.

Park Y.-H. Kim J. N. Jeong S. H. Choi J. E. Lee S.-H. Choi B. H. Lee J. P. Sohn K. H. Park K. L. Kim M-.K. , and Son S. W. , “Assessment of Dermal Toxicity of Nanosilica Using Cultured Keratinocytes, a Human Skin Equivalent Model and an In Vivo Model,” Toxicology 267, No. 1-3 (2010): 178–181.

Mbah C. J. Uzor P. F. , and Omeje E. O. , “Perspectives on Transdermal Drug Delivery,” Journal of Chemical and Pharmaceutical Research 3, no. 3 (2011): 680–700.

Des Rieux A. Fievez V. Garinot M. Schneider Y.-J. , and Preat V. , “Nanoparticles as Potential Oral Delivery Systems of Proteins and Vaccines: A Mechanistic Approach,” Journal of Controlled Release 116, no. 1 (2006): 1–27.

See Love , supra note 6.

Mahler G. J. Esch M. B. Tako E. Southard T. L. Archer S. D. Glahn R. P. , and Shuler M. L. , “Oral Exposure to Polystyrene Nanoparticles Affects Iron Absorption,” Nature Nanotechnology 7, no. 4 (2012): 264–271.

Moulari B. Pertuit D. Pellequer Y. , and Lamprecht A. , “The Targeting of Surface Modified Silica Nanoparticles to Inflamed Tissue in Experimental Colitis,” Biomaterials 29, no. 34 (2008): 4554–4560. 29. Jain A. K. Swarnakar N. K. Das M. Godugu C. Singh R. P. Rao P. R. , and Jain S. , “Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model,” Molecular Pharmaceutics 8, no. 4 (2011): 1140–1151.

Id.

See Etheridge , supra note 3.

See Love , supra note 6.

Al-Jamal W. T. Al-Jamal K. T. Bomans P. H. Frederik P. M. , and Kostarelos K. , “Functionalized-Quantum-Dot-Liposome Hybrids as Multimodal Nanoparticles for Cancer,” Small 4, no. 9 (2008): 1406–1415; Devalapally H. Duan Z. Seiden M. V. , and Amiji M. M. , “Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles,” Clinical Cancer Research 14, no. 10 (2008): 3193–3203; Gannon C. J. Cherukuri P. Yakobson B. I. Cognet L. Kanzius J. S. Kittrell C. Weisman R. B. Pasquali M. Schmidt H. K. Smalley R. E. , and Curley S. A. , “Carbon Nanotube-Enhanced Thermal Destruction of Cancer Cells in a Noninvasive Radio-frequency Field,” Cancer 110, no. 12 (2007): 2654–2665.

Singh S. K. Singh M. K. Nayak M. K. Kumari S. Shrivastava S. Gracio J. J. A. , and Dash D. , “Thrombus Inducing Property of Atomically Thin Graphene Oxide Sheets,” ACS Nano 5, no. 6 (2011): 4987–4996.

Id.

See Marquis , supra note 5; A. Maynard D. Warheit D. B. , and Philbert M. A. , “The New Toxicology of Sophisticated Materials: Nanotoxicology and Beyond,” Toxicological Sciences 120, no. S1 (2011): S109–S129.

See Lin , supra note 2.

Lundqvist M. Stigler J. Elia G. Lynch I. Cedervall T. , and Dawson K. A. , “Nanoparticle Size and Surface Properties Determine the Protein Corona with Possible Implications for Biological Impacts,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 38 (2008): 14265–14270.

Lin Y. S. and Haynes C. L. , “Impacts of Mesoporous Silica Nanoparticle Size, Pore Ordering, and Pore Integrity on Hemolytic Activity,” Journal of the American Chemical Society 132, no. 13 (2010): 4834–4842.

Gilliam L. A. A. and St. Clair D. K. , “Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress,” Antioxidant & Redox Signaling 15, no. 9 (2011): 2543–2563.

National Research Council, Toxicity Testing in the 21st Century: A Vision and a Strategy (Washington, D.C.: National Academy Press, 2007).

See Maynard , supra note 36.